Shattuck Labs Announces Phase 1 Data for SL-325 Antibody
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 2 days ago
0mins
Source: Newsfilter
- Immunogenicity Profile: Among 72 participants, only 3.7% (2 individuals) developed antidrug antibodies, with no impact on pharmacokinetics or receptor occupancy, indicating SL-325's potentially best-in-class immunogenicity profile that may enhance clinical efficacy.
- Complete DR3 Occupancy: Complete blockade of TL1A binding was observed at doses of 0.1 mg/kg and above in all participants, with sustained inhibition lasting over three months, suggesting SL-325's potential for long-term efficacy in treating inflammatory bowel disease.
- Favorable Safety Profile: SL-325 was well tolerated across all dose levels with no serious adverse events reported, and all treatment-related adverse events were Grade 1, aligning with the safety profile of TL1A inhibitors and enhancing its clinical application prospects.
- RECEPTIVE-CD1 Trial Plans: The RECEPTIVE-CD1 trial, expected to initiate in Q3 2026, aims to enroll approximately 174 patients with moderate-to-severe Crohn's disease to evaluate the safety and efficacy of SL-325, with preliminary results anticipated in the first half of 2028, potentially offering new treatment options in this area.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy STTK?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on STTK
Wall Street analysts forecast STTK stock price to rise
3 Analyst Rating
2 Buy
1 Hold
0 Sell
Moderate Buy
Current: 3.900
Low
4.00
Averages
8.33
High
15.00
Current: 3.900
Low
4.00
Averages
8.33
High
15.00
About STTK
Shattuck Labs, Inc. is a biotechnology company. The Company is engaged in the development of treatments for inflammatory and immune-mediated diseases. Its lead product candidate, SL-325, is a monoclonal antibody that is designed to bind to death receptor 3 (DR3) and inhibit its interaction with its ligand, TL1A. TL1A is a costimulatory ligand in the tumor necrosis factor superfamily, which activates immune responses through binding a single receptor, DR3. The Company is conducting a Phase I clinical trial in healthy volunteers. In addition, the Company is also developing SL-425, a half-life extended version of SL-325. It is also developing multiple preclinical DR3-based bispecific antibodies, which are designed to inhibit both the DR3/TL1A axis and another biologically relevant target for the treatment of patients with inflammatory bowel disease.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Shattuck Labs Exercises 50.6M Warrants Generating $54.9M
- Warrant Exercise Overview: Shattuck Labs has received notices to exercise approximately 50.6 million warrants, which represents 96% of those issued in its August 2025 private placement, and is expected to generate around $54.9 million in gross proceeds, significantly enhancing its liquidity.
- Future Cash Inflows: As of March 31, 2026, the company had already received $5.6 million from the exercise of about 5.15 million warrants, and it anticipates an additional $49.3 million from approximately 45.44 million warrants, further solidifying its financial foundation.
- Cash Reserves Status: Shattuck Labs reported $90.4 million in cash, cash equivalents, and short-term investments as of March 31, 2026, and with the expected warrant proceeds, the company projects it can sustain operations into 2029, indicating strong financial health.
- Strategic Fund Utilization: The exercise of these warrants not only bolsters Shattuck Labs' financial strength but also secures funding for future R&D and operations, further advancing its strategic development in the biotechnology sector.
See More
Shattuck Labs Prices Public Offering at $4 per Share
- Public Offering Details: Shattuck Labs has priced its public offering at $4 per share for 10.88 million shares, expecting gross proceeds of approximately $75 million, indicating a proactive financing strategy in the capital markets.
- Pre-Funded Warrants: The company is also offering pre-funded warrants to purchase up to 7.87 million shares at $3.9999 each, enhancing investor participation and interest in the offering.
- Underwriter Team: The offering is managed by Leerink Partners, J.P. Morgan, Piper Sandler, and Cantor, reflecting strong market confidence in Shattuck Labs' prospects.
- Stock Performance Volatility: STTK has traded between $0.71 and $8.33 over the past year, closing at $4.27, although it has seen a pre-market decline of 4.92%, indicating some volatility but overall market resilience.
See More
Shattuck Labs Prices Public Offering at $4.00 per Share
- Offering Size: Shattuck Labs announced a public offering of 10,879,376 shares at a price of $4.00 per share, with expected gross proceeds of approximately $75 million, indicating strong demand in the capital markets.
- Pre-Funded Warrants: The company is also offering pre-funded warrants to purchase up to 7,870,624 shares at $3.9999 each, with an exercise price of just $0.0001, enhancing investor participation and interest.
- Underwriter Option: Shattuck has granted underwriters a 30-day option to purchase an additional 2,812,500 shares at the public offering price, reflecting confidence in market demand and providing flexibility for future financing.
- Expected Closing: The offering is anticipated to close on June 11, 2026, subject to customary closing conditions, which, if successful, will provide crucial funding for the company's ongoing research and development efforts.
See More
Shattuck Labs Initiates Public Offering of Common Stock
- Public Offering Launch: Shattuck Labs (STTK) has commenced a public offering of common stock or pre-funded warrants for certain investors, indicating the company's proactive approach in capital markets.
- Underwriter Option: The company expects to grant underwriters a 30-day option to purchase up to an additional 15% of common stock, a strategy aimed at enhancing fundraising capabilities and reducing financing costs.
- Stock Price Volatility: Following the public offering announcement, STTK's stock price fell 15.69% to $3.60 in after-hours trading, reflecting market caution regarding the offering.
- Funding Continuation: Shattuck Labs recently secured $54.9 million from warrant exercises, extending its cash runway into 2029, demonstrating a proactive strategy in financial management.
See More
Shattuck Labs Initiates Public Offering of Common Stock
- Public Offering Launch: Shattuck Labs has announced the initiation of a public offering to issue common stock or pre-funded warrants to select investors, indicating the company's proactive stance in capital markets aimed at raising funds for its R&D projects.
- Underwriter Selection: The offering is being managed by prominent financial institutions including Leerink Partners, J.P. Morgan, Piper Sandler, and Cantor, which enhances market confidence in the company's financing activities through the involvement of reputable underwriters.
- Additional Share Option: Shattuck expects to grant underwriters a 30-day option to purchase up to an additional 15% of shares, a strategy that could increase the offering size if demand is strong, thereby providing the company with greater financial flexibility.
- Market Condition Uncertainty: The completion timing and size of the public offering remain uncertain and are subject to market and other conditions, reflecting the company's cautious approach in the current economic environment while signaling investors to stay alert to market developments.
See More
Shattuck Labs Announces Phase 1 Data for SL-325 Antibody
- Immunogenicity Profile: Among 72 participants, only 3.7% (2 individuals) developed antidrug antibodies, with no impact on pharmacokinetics or receptor occupancy, indicating SL-325's potentially best-in-class immunogenicity profile that may enhance clinical efficacy.
- Complete DR3 Occupancy: Complete blockade of TL1A binding was observed at doses of 0.1 mg/kg and above in all participants, with sustained inhibition lasting over three months, suggesting SL-325's potential for long-term efficacy in treating inflammatory bowel disease.
- Favorable Safety Profile: SL-325 was well tolerated across all dose levels with no serious adverse events reported, and all treatment-related adverse events were Grade 1, aligning with the safety profile of TL1A inhibitors and enhancing its clinical application prospects.
- RECEPTIVE-CD1 Trial Plans: The RECEPTIVE-CD1 trial, expected to initiate in Q3 2026, aims to enroll approximately 174 patients with moderate-to-severe Crohn's disease to evaluate the safety and efficacy of SL-325, with preliminary results anticipated in the first half of 2028, potentially offering new treatment options in this area.
See More
Shattuck Labs Exercises 50.6M Warrants Generating $54.9M
- Warrant Exercise Overview: Shattuck Labs has received notices to exercise approximately 50.6 million warrants, which represents 96% of those issued in its August 2025 private placement, and is expected to generate around $54.9 million in gross proceeds, significantly enhancing its liquidity.
- Future Cash Inflows: As of March 31, 2026, the company had already received $5.6 million from the exercise of about 5.15 million warrants, and it anticipates an additional $49.3 million from approximately 45.44 million warrants, further solidifying its financial foundation.
- Cash Reserves Status: Shattuck Labs reported $90.4 million in cash, cash equivalents, and short-term investments as of March 31, 2026, and with the expected warrant proceeds, the company projects it can sustain operations into 2029, indicating strong financial health.
- Strategic Fund Utilization: The exercise of these warrants not only bolsters Shattuck Labs' financial strength but also secures funding for future R&D and operations, further advancing its strategic development in the biotechnology sector.
See More
Shattuck Labs Prices Public Offering at $4 per Share
- Public Offering Details: Shattuck Labs has priced its public offering at $4 per share for 10.88 million shares, expecting gross proceeds of approximately $75 million, indicating a proactive financing strategy in the capital markets.
- Pre-Funded Warrants: The company is also offering pre-funded warrants to purchase up to 7.87 million shares at $3.9999 each, enhancing investor participation and interest in the offering.
- Underwriter Team: The offering is managed by Leerink Partners, J.P. Morgan, Piper Sandler, and Cantor, reflecting strong market confidence in Shattuck Labs' prospects.
- Stock Performance Volatility: STTK has traded between $0.71 and $8.33 over the past year, closing at $4.27, although it has seen a pre-market decline of 4.92%, indicating some volatility but overall market resilience.
See More
Shattuck Labs Prices Public Offering at $4.00 per Share
- Offering Size: Shattuck Labs announced a public offering of 10,879,376 shares at a price of $4.00 per share, with expected gross proceeds of approximately $75 million, indicating strong demand in the capital markets.
- Pre-Funded Warrants: The company is also offering pre-funded warrants to purchase up to 7,870,624 shares at $3.9999 each, with an exercise price of just $0.0001, enhancing investor participation and interest.
- Underwriter Option: Shattuck has granted underwriters a 30-day option to purchase an additional 2,812,500 shares at the public offering price, reflecting confidence in market demand and providing flexibility for future financing.
- Expected Closing: The offering is anticipated to close on June 11, 2026, subject to customary closing conditions, which, if successful, will provide crucial funding for the company's ongoing research and development efforts.
See More
Shattuck Labs Initiates Public Offering of Common Stock
- Public Offering Launch: Shattuck Labs (STTK) has commenced a public offering of common stock or pre-funded warrants for certain investors, indicating the company's proactive approach in capital markets.
- Underwriter Option: The company expects to grant underwriters a 30-day option to purchase up to an additional 15% of common stock, a strategy aimed at enhancing fundraising capabilities and reducing financing costs.
- Stock Price Volatility: Following the public offering announcement, STTK's stock price fell 15.69% to $3.60 in after-hours trading, reflecting market caution regarding the offering.
- Funding Continuation: Shattuck Labs recently secured $54.9 million from warrant exercises, extending its cash runway into 2029, demonstrating a proactive strategy in financial management.
See More
Shattuck Labs Initiates Public Offering of Common Stock
- Public Offering Launch: Shattuck Labs has announced the initiation of a public offering to issue common stock or pre-funded warrants to select investors, indicating the company's proactive stance in capital markets aimed at raising funds for its R&D projects.
- Underwriter Selection: The offering is being managed by prominent financial institutions including Leerink Partners, J.P. Morgan, Piper Sandler, and Cantor, which enhances market confidence in the company's financing activities through the involvement of reputable underwriters.
- Additional Share Option: Shattuck expects to grant underwriters a 30-day option to purchase up to an additional 15% of shares, a strategy that could increase the offering size if demand is strong, thereby providing the company with greater financial flexibility.
- Market Condition Uncertainty: The completion timing and size of the public offering remain uncertain and are subject to market and other conditions, reflecting the company's cautious approach in the current economic environment while signaling investors to stay alert to market developments.
See More
Shattuck Labs Announces Phase 1 Data for SL-325 Antibody
- Immunogenicity Profile: Among 72 participants, only 3.7% (2 individuals) developed antidrug antibodies, with no impact on pharmacokinetics or receptor occupancy, indicating SL-325's potentially best-in-class immunogenicity profile that may enhance clinical efficacy.
- Complete DR3 Occupancy: Complete blockade of TL1A binding was observed at doses of 0.1 mg/kg and above in all participants, with sustained inhibition lasting over three months, suggesting SL-325's potential for long-term efficacy in treating inflammatory bowel disease.
- Favorable Safety Profile: SL-325 was well tolerated across all dose levels with no serious adverse events reported, and all treatment-related adverse events were Grade 1, aligning with the safety profile of TL1A inhibitors and enhancing its clinical application prospects.
- RECEPTIVE-CD1 Trial Plans: The RECEPTIVE-CD1 trial, expected to initiate in Q3 2026, aims to enroll approximately 174 patients with moderate-to-severe Crohn's disease to evaluate the safety and efficacy of SL-325, with preliminary results anticipated in the first half of 2028, potentially offering new treatment options in this area.
See More
